In melanoma therapy, BRAFV600E inhibitors are commonly coapplied with an assigned MEK1/2 inhibitor to efficiently block ERK signaling in tumor cells and thus to provide development of resistance mechanisms. Here, MAP2K1 is linked to melanoma.